To study the role of Oxybutinin in infants affected with posterior urethral valve

Effect of early administration of oxybutynin on outcome of posterior urethral valve in infants: a randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/08/056095

Enrollment

Registered

2023-08-03

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q642- Congenital posterior urethral valves

Interventions

Intervention1: Administration of Oxybutinin in children with diagnosed valve bladder (after posterior urethral valve fulgration) after urodynamic studies: Oxybutinin will be administered orally at a

Eligibility

Inclusion criteria

Inclusion criteria: Infants with bladder dysfunction due to posterior urethral valve who have been adequately fulgurated.

Exclusion criteria

Exclusion criteria: Infants who have not undergone adequately fulgurated or who have undergone upper urinary tract diversion procedures.

Design outcomes

Primary

Measure	Time frame
Urodynamic study will be done to record voiding pressure, bladder volume with respect to age & bladder compliance.Timepoint: Urodynamic study will be done prior to administration of oxybutynin and 3 months after administration of oxybutynin.	—

Secondary

Measure	Time frame
Clinical improvement Radiological improvement in bladder outline & upper renal tract UTI & efficacy/side effects of oxybutyninTimepoint: Baseline before starting oxybutynin & 3 months after starting oxybutynin.	—

Countries

India

Contacts

Public ContactProfessor Jai Kumar Mahajan

Post Graduate Institute of Medical Education and Research

jkmahajan@gmail.com7087008325

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026